Related Experiment Video
Updated: Mar 14, 2026

Fabrication of Tongue Extracellular Matrix and Reconstitution of Tongue Squamous Cell Carcinoma In Vitro
Published on: June 20, 2018
FRMD4A: A potential therapeutic target for the treatment of tongue squamous cell carcinoma
Xianghuai Zheng1, Bo Jia1, Xi Lin1
1Laboratory for Oral Diseases, Department of Oral Surgery, Guangdong Provincial Stomatological Hospital, Southern Medical University, Guangzhou, Guangdong 510280, P.R. China.
Abstract:
The aim of the present study was to identify agents capable of inhibiting the invasion and metastasis of tongue squamous cell carcinoma and thereby improve the outcomes of patients suffering from tongue cancer. FRMD4A antibodies were used to probe 78 paraffin-embedded specimens of tongue squamous cell carcinoma and 15 normal tongue tissues, which served as controls. Immunohistochemical methods were then used for analysis. Clinical pathological parameters were obtained, and the association between FRMD4A expression in the samples and the pathological parameters was analyzed. The human tongue cancer cell line CAL27 was used to study the effects of FRMD4A. CAL27 cells were transfected with small-interfering RNA against FRMD4A (FRMD4A-siRNA) and the mRNA and protein levels of FMRD4A were then evaluated by RT-qPCR and western blot analysis, respectively. The proliferation and cell-cycle assays of CAL27 cells were evaluated using the CCK8 method and flow cytometry. The invasion and migration of the cells were measured using a Matrigel invasion chamber and a scratch assay, respectively. The results showed FRMD4A overexpression in tongue squamous cell carcinoma, and the positive reaction was predominately located in the cytoplasm. Tumor clinical stage and lymph node metastasis showed a statistically significant correlation with FRMD4A expression. Transient silencing of the FRMD4A gene for 24 and 48 h significantly decreased the mRNA and protein expression of FRMD4A, respctively. Silencing FRMD4A gene reduced the proliferation of CAL27 cells and led to cell cycle arrest in the G1 phase, as well as significantly suppressing the migration and invasion capacity of CAL27 cells. The findings of the present study suggest that FRMD4A expression correlates with the development of tongue squamous cell carcinoma. For this reason, FRMD4A merits further study as it may be suitable for use as a therapeutic agent in antitumor treatment regimens.
Insights
FRMD4A is overexpressed in tongue squamous cell carcinoma and correlates with tumor stage and metastasis. Inhibiting FRMD4A reduces cancer cell proliferation, migration, and invasion, suggesting its potential as a therapeutic target for tongue cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Tongue squamous cell carcinoma (TSCC) invasion and metastasis significantly impact patient outcomes.
- Identifying novel therapeutic targets for TSCC is crucial for improving treatment efficacy.
Purpose of the Study:
- To investigate the role of FRMD4A in TSCC progression.
- To evaluate FRMD4A as a potential therapeutic target for tongue cancer.
Main Methods:
- Immunohistochemistry was used to analyze FRMD4A expression in 78 TSCC specimens and 15 normal tissues.
- FRMD4A gene silencing was performed in the CAL27 tongue cancer cell line using FRMD4A-siRNA.
- Cell proliferation, cell cycle, migration, and invasion assays were conducted.
Main Results:
- FRMD4A was found to be overexpressed in TSCC tissues, with expression levels correlating with tumor clinical stage and lymph node metastasis.
- FRMD4A gene silencing significantly reduced TSCC cell proliferation, induced G1 phase arrest, and suppressed cell migration and invasion.
- FRMD4A overexpression is linked to TSCC development and progression.
Conclusions:
- FRMD4A plays a significant role in the development and metastasis of tongue squamous cell carcinoma.
- FRMD4A represents a promising therapeutic target for tongue cancer treatment.
More Related Videos
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Targeted Cancer Therapies
There are several types of targeted therapies against...

